Abstract
We report the development of a potent, selective histone deacetylase 6 (HDAC6) inhibitor. This HDAC6 inhibitor blocks growth of normal and transformed cells but does not induce death of normal cells. The HDAC6 inhibitor alone is as effective as paclitaxel in anticancer activity in tumor-bearing mice.
Keywords:
HDAC; cancer; tubulin.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylation / drug effects
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / chemistry
-
Benzeneacetamides / chemistry*
-
Benzeneacetamides / pharmacology*
-
Cell Death / drug effects
-
Cell Proliferation / drug effects
-
Histone Deacetylase 6
-
Histone Deacetylase Inhibitors / chemical synthesis*
-
Histone Deacetylase Inhibitors / chemistry
-
Histone Deacetylases / genetics*
-
Hydroxamic Acids / chemistry*
-
Hydroxamic Acids / pharmacology*
-
Mice
-
Molecular Structure
-
Paclitaxel
-
Tubulin / metabolism
Substances
-
Antineoplastic Agents
-
Benzeneacetamides
-
Histone Deacetylase Inhibitors
-
Hydroxamic Acids
-
N-hydroxy-4-((N-(2-hydroxyethyl)-2-phenylacetamido)methyl)benzamide
-
Tubulin
-
Hdac6 protein, mouse
-
Histone Deacetylase 6
-
Histone Deacetylases
-
Paclitaxel